Literature DB >> 23734772

Role of the eIF4E binding protein 4E-BP1 in regulation of the sensitivity of human pancreatic cancer cells to TRAIL and celastrol-induced apoptosis.

Reka Chakravarthy1, Michael J Clemens, Grisha Pirianov, Nectarios Perdios, Satvinder Mudan, Judith E Cartwright, Androulla Elia.   

Abstract

BACKGROUND INFORMATION: Tumour cells can be induced to undergo apoptosis after treatment with the tumour necrosis factor α-related death-inducing ligand (TRAIL). Although human pancreatic cancer cells show varying degrees of response they can be sensitised to the pro-apoptotic effects of TRAIL in the presence of celastrol, a natural compound extracted from the plant Tripterygium wilfordii Hook F. One important aspect of the cellular response to TRAIL is the control of protein synthesis, a key regulator of which is the eukaryotic initiation factor 4E-binding protein, 4E-BP1.
RESULTS: We examined the effects of celastrol and TRAIL in several pancreatic cancer cell lines. In cells that are normally resistant to TRAIL, synergistic effects of TRAIL plus celastrol on commitment to apoptosis and inhibition of protein synthesis were observed. These were associated with a strong up-regulation and dephosphorylation of 4E-BP1. The enhancement of 4E-BP1 expression, which correlated with a threefold increase in the level of the 4E-BP1 transcript, was blocked by inhibitors of reactive oxygen species and the JNK protein kinase. When the expression of 4E-BP1 was reduced by an inducible micro-RNA, TRAIL-mediated apoptosis was inhibited.
CONCLUSION: These results suggest that 4E-BP1 plays a critical role in the mechanism by which TRAIL and celastrol together cause apoptotic cell death in human pancreatic tumour cells.
© 2013 Société Française des Microscopies and Société de Biologie Cellulaire de France. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  anti-cancer; protein synthesis; therapeutic; triterpene; tumour necrosis factor α-related apoptosis-inducing ligand (TRAIL)

Mesh:

Substances:

Year:  2013        PMID: 23734772     DOI: 10.1111/boc.201300021

Source DB:  PubMed          Journal:  Biol Cell        ISSN: 0248-4900            Impact factor:   4.458


  10 in total

1.  Celastrol inhibits migration and invasion through blocking the NF-κB pathway in ovarian cancer cells.

Authors:  Zhongye Wang; Zhenyuan Zhai; Xiulan Du
Journal:  Exp Ther Med       Date:  2017-06-08       Impact factor: 2.447

2.  High expression of neuroguidin increases the sensitivity of acute myeloid leukemia cells to chemotherapeutic drugs.

Authors:  Kejun Chen; Shuqing Lü; Hui Cheng; Gusheng Tang; Min Liu; Hong Zhou; Jianmin Wang
Journal:  J Hematol Oncol       Date:  2015-02-19       Impact factor: 17.388

3.  Implication of 4E-BP1 protein dephosphorylation and accumulation in pancreatic cancer cell death induced by combined gemcitabine and TRAIL.

Authors:  Androulla Elia; Ricky Henry-Grant; Charlotte Adiseshiah; Catherine Marboeuf; Rebecca J Buckley; Michael J Clemens; Satvinder Mudan; Stéphane Pyronnet
Journal:  Cell Death Dis       Date:  2017-12-12       Impact factor: 8.469

4.  Matrine reduces the proliferation of A549 cells via the p53/p21/PCNA/eIF4E signaling pathway.

Authors:  Zhiyan Lu; Youzhang Xiao; Xing Liu; Zaipeng Zhang; Feng Xiao; Yongyi Bi
Journal:  Mol Med Rep       Date:  2017-03-16       Impact factor: 2.952

Review 5.  Compounds From Celastraceae Targeting Cancer Pathways and Their Potential Application in Head and Neck Squamous Cell Carcinoma: A Review.

Authors:  Camila Hernandes; Ana Maria Soares Pereira; Patricia Severino
Journal:  Curr Genomics       Date:  2017-02       Impact factor: 2.236

6.  The coordinated effects of Apatinib and Tripterine on the proliferation, invasiveness and apoptosis of human hepatoma Hep3B cells.

Authors:  Huihui Li; Yichang Fan; Fan Yang; Lei Zhao; Bangwei Cao
Journal:  Oncol Lett       Date:  2018-05-07       Impact factor: 2.967

7.  Protective effect of celastrol on myocardial ischemia-reperfusion injury.

Authors:  Xiaoyan Li; Nan Wu; Lu Zou; Dalin Jia
Journal:  Anatol J Cardiol       Date:  2017-12       Impact factor: 1.596

8.  Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer.

Authors:  Carlotta Spano; Giulia Grisendi; Giulia Golinelli; Filippo Rossignoli; Malvina Prapa; Marco Bestagno; Olivia Candini; Tiziana Petrachi; Alessandra Recchia; Francesca Miselli; Giulia Rovesti; Giulia Orsi; Antonino Maiorana; Paola Manni; Elena Veronesi; Maria Serena Piccinno; Alba Murgia; Massimo Pinelli; Edwin M Horwitz; Stefano Cascinu; Pierfranco Conte; Massimo Dominici
Journal:  Sci Rep       Date:  2019-02-11       Impact factor: 4.379

9.  Impact of the secretome of activated pancreatic stellate cells on growth and differentiation of pancreatic tumour cells.

Authors:  Aseel J Marzoq; Shakhawan A Mustafa; Luzia Heidrich; Jörg D Hoheisel; Mohamed Saiel Saeed Alhamdani
Journal:  Sci Rep       Date:  2019-03-28       Impact factor: 4.379

10.  Peptide deformylase inhibitor actinonin reduces celastrol's HSP70 induction while synergizing proliferation inhibition in tumor cells.

Authors:  Bin Peng; Xue Zhang; Fanfan Cao; Ying Wang; Limin Xu; Lu Cao; Chunxin Yang; Maoquan Li; Georges Uzan; Denghai Zhang
Journal:  BMC Cancer       Date:  2014-03-04       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.